|
|
|
Cancer News |
Saturday July 5, 2008
The latest news on cancer treatment, cancer research, oncology advances, and cancer clinical trials.
|
 |
Pegylated liposomal doxorubicin effective in hard-to-treat cutaneous T-cell lymphoma ...more
|
 |
Education reduces children's need for anesthesia during radiotherapy ...more
|
 |
Survival after radical cystectomy linked to number of lymph nodes removed ...more
|
 |
Maribavir prevents CMV infection after stem cell transplant ...more
|
 |
Anti-thrombosis benefit unclear in cancer patients with catheters ...more
|
 |
GM-CSF potentiates rituximab in follicular lymphoma ...more
|
| More Cancer News |
|
|
|
|
Hot Spot |
|

OncoLink has created an individualized plan of care based on the Institute of Medicine recommendations for cancer survivors. This free and easy to use program provides cancer survivors with information regarding the health risks they face as a result of cancer therapies. It encourages them to review the plan with their healthcare team to further assess their risk and become active participants in their follow up care.
Develop your survivorship care plan today!
Oncolife en espanõl
|
|
|
|
 |
What's New |
Experts on Call: Dr. Kevin Fox discusses OncoType Dx
Tune in to see Kevin Fox, MD, Medical Director for the Rena Rowan Breast Center and Mariann T. and Robert J. MacDonald Professor of Medicine discuss the OncoType Dx test. This podcast addresses who should have the test, what information they will gain from it and how it may be used in the future.
OncoLink at ASCO 2008
OncoLink reporters provide in-depth coverage of scientific presentations from the 44th Annual ASCO Meeting.
View all new items
|
|
|
|
|
Cancer Awareness |
|
Skin cancer is the number one cancer diagnosis in the United States - more common than all breast, prostate, and lung cancers combined. The majority of cases are caused by sun damage to skin cells, and therefore are largely preventable. Every year in July we recognize UV Safety month to remind people of the importance of sun safety. Get the facts.
|
|
|
|